DUBLIN, Ireland and BRIDGEWATER, N.J., Dec. 11, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced its participation in the 42nd Annual JP Morgan Healthcare Conference. Amarin’s president and chief executive officer, Patrick Holt, is scheduled to present at the conference on January 10, 2024.
42nd Annual J.P. Morgan Healthcare Conference (January 8th-11th, 2024; San Francisco, California)
Date/Time: January 10, 2024, 4:30 p.m. ET/ 1:30 p.m. PST
The conference presentation will be webcast live and archived on the Company’s website in the Investor Relations section under Events and Presentations at Events | Amarin Corporation plc.
About Amarin
Amarin is an innovative pharmaceutical company leading a new paradigm in cardiovascular disease management. We are committed to increasing the scientific understanding of the cardiovascular risk that persists beyond traditional therapies and advancing the treatment of that risk for patients worldwide. Amarin has offices in Bridgewater, New Jersey in the United States, Dublin in Ireland, Zug in Switzerland, and other countries in Europe as well as commercial partners and suppliers around the world.
Availability of Other Information About Amarin
Amarin communicates with its investors and the public using the company website (www.amarincorp.com) and the investor relations website (investor.amarincorp.com), including but not limited to investor presentations and FAQs, Securities and Exchange Commission filings, press releases, public conference calls and webcasts. The information that Amarin posts on these channels and websites could be deemed to be material information. As a result, Amarin encourages investors, the media and others interested in Amarin to review the information that is posted on these channels, including the investor relations website, on a regular basis. This list of channels may be updated from time to time on Amarin’s investor relations website and may include social media channels. The contents of Amarin’s website or these channels, or any other website that may be accessed from its website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933.
Amarin Contact Information
Investor Inquiries:
Investor Relations
Amarin Corporation plc
This email address is being protected from spambots. You need JavaScript enabled to view it. (investor inquiries)
Media Inquiries:
Communications
Amarin Corporation plc
This email address is being protected from spambots. You need JavaScript enabled to view it. (media inquiries)
| Last Trade: | US$0.50 |
| Daily Change: | -0.02 -3.85 |
| Daily Volume: | 2,005,377 |
| Market Cap: | US$205.580M |
October 01, 2024 | |
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
